Feb 24 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O:
REGENERON: DB-OTO RESULTS SHOW CLINICALLY MEANINGFUL HEARING IMPROVEMENTS IN NEARLY ALL CHILDREN WITH PROFOUND GENETIC HEARING LOSS IN CHORD TRIAL
REGENERON: 10 OF 11 CHILDREN WITH AT LEAST ONE POST-TREATMENT ASSESSMENT SHOWED NOTABLE IMPROVEMENTS IN HEARING IN PHASE 1/2 CHORD TRIAL
REGENERON: 72-WEEK RESULTS FOR DB-OTO SHOWS SPEECH AND DEVELOPMENT PROGRESS IN FIRST CHILD DOSED AT 10 MONTHS OF AGE
Source text: [ID:]
Further company coverage: REGN.O
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.